{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:53:14Z","timestamp":1789699994061,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Australian Centre for Research Excellence in Malaria Elimination, funded by the NHMRC","award":["1134989"],"award-info":[{"award-number":["1134989"]}]},{"name":"Australian National Health and Medical Research Council of Australia (NHMRC) Investigator","award":["1196068"],"award-info":[{"award-number":["1196068"]}]},{"name":"NHMRC Program","award":["1132975"],"award-info":[{"award-number":["1132975"]}]},{"name":"Practitioner Fellowship","award":["1041802"],"award-info":[{"award-number":["1041802"]}]},{"name":"Practitioner Fellowship","award":["NCT02389348"],"award-info":[{"award-number":["NCT02389348"]}]},{"name":"Practitioner Fellowship","award":["NCT02573857"],"award-info":[{"award-number":["NCT02573857"]}]},{"name":"Practitioner Fellowship","award":["ACTRN12613000522718"],"award-info":[{"award-number":["ACTRN12613000522718"]}]},{"name":"Practitioner Fellowship","award":["ACTRN12613000527763"],"award-info":[{"award-number":["ACTRN12613000527763"]}]},{"name":"Practitioner Fellowship","award":["ACTRN12612000814875"],"award-info":[{"award-number":["ACTRN12612000814875"]}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["095909\/Z\/11\/Z"],"award-info":[{"award-number":["095909\/Z\/11\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Global Health Innovation and Technology Fund","award":["G2014-108"],"award-info":[{"award-number":["G2014-108"]}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of artemisinin-based combination therapies (ACTs), the first-line treatments for uncomplicated falciparum malaria, has been declining in malaria-endemic countries due to the emergence of malaria parasites resistant to these compounds. Novel alternative therapies are needed urgently to prevent the likely surge in morbidity and mortality due to failing ACTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study investigates the efficacy of the combination of two novel drugs, OZ439 and DSM265, using a biologically informed within-host mathematical model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A within-host model was developed, which accounts for the differential killing of these compounds against different stages of the parasite\u2019s life cycle and accommodates the pharmacodynamic interaction between the drugs. Data of healthy volunteers infected with falciparum malaria collected from four trials (three that administered OZ439 and DSM265 alone, and the fourth a combination of OZ439 and DSM265) were analysed. Model parameters were estimated in a hierarchical Bayesian framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The posterior predictive simulations of our model predicted that 800\u2009mg of OZ439 combined with 450\u2009mg of DSM265, which are within the safe and tolerable dose range, can provide above 90% cure rates 42\u2009days after drug administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results show that the combination of OZ439 and DSM265 can be a promising alternative to replace ACTs. Our model can be used to inform future Phase 2 and 3 clinical trials of OZ439\/DSM265, fast-tracking the deployment of this combination therapy in the regions where ACTs are failing. The dosing regimens that are shown to be efficacious and within safe and tolerable limits are suggested for future investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkab181","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T07:35:57Z","timestamp":1620372957000},"page":"2325-2334","source":"Crossref","is-referenced-by-count":16,"title":["Seeking an optimal dosing regimen for OZ439\/DSM265 combination therapy for treating uncomplicated falciparum malaria"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-3672","authenticated-orcid":false,"given":"Saber","family":"Dini","sequence":"first","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie G.","family":"Zaloumis","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Price","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia"},{"name":"Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Gobeau","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"K\u00fcmmel","sequence":"additional","affiliation":[{"name":"IntiQuan, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Cherkaoui","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J.","family":"Moehrle","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"QIMR Berghofer Medical Research Institute, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"2021081309085885100_dkab181-B1","year":"2015"},{"key":"2021081309085885100_dkab181-B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"van der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"2021081309085885100_dkab181-B3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"key":"2021081309085885100_dkab181-B4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"2021081309085885100_dkab181-B5","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.EI10-0013-2016","article-title":"Artemisinin-resistant Plasmodium falciparum malaria","volume":"4","author":"Fairhurst","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2021081309085885100_dkab181-B6","doi-asserted-by":"crossref","first-page":"e01068-18","DOI":"10.1128\/AAC.01068-18","article-title":"Investigating the efficacy of triple artemisinin-based combination therapies for treating Plasmodium falciparum malaria patients using mathematical modeling","volume":"62","author":"Dini","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309085885100_dkab181-B7","doi-asserted-by":"crossref","first-page":"e01371-19","DOI":"10.1128\/AAC.01371-19","article-title":"A single-dose combination study with the experimental antimalarials artefenomel and DSM265 to determine safety and antimalarial activity against blood-stage Plasmodium falciparum in healthy volunteers","volume":"64","author":"McCarthy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309085885100_dkab181-B8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar J"},{"key":"2021081309085885100_dkab181-B9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1475-2875-8-253","article-title":"Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance","volume":"8","author":"White","year":"2009","journal-title":"Malar J"},{"key":"2021081309085885100_dkab181-B10","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021081309085885100_dkab181-B11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1128\/AAC.46.4.1026-1031.2002","article-title":"Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens","volume":"46","author":"Gordi","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309085885100_dkab181-B12","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00574-16","article-title":"Comparison of the exposure time dependence of the activities of synthetic ozonide antimalarials and dihydroartemisinin against K13 wild-type and mutant Plasmodium falciparum strains","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309085885100_dkab181-B13","doi-asserted-by":"crossref","first-page":"e01837-18","DOI":"10.1128\/AAC.01837-18","article-title":"DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum","volume":"63","author":"Collins","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309085885100_dkab181-B14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021081309085885100_dkab181-B15","doi-asserted-by":"crossref","first-page":"296ra111","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci Transl Med"},{"key":"2021081309085885100_dkab181-B16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2125.2012.04368.x","article-title":"First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials","volume":"75","author":"Moehrle","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2021081309085885100_dkab181-B17","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.01172-15","article-title":"Incorporating stage-specific drug action into pharmacological modeling of antimalarial drug treatment","volume":"60","author":"Hodel","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081309085885100_dkab181-B18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1017\/S0031182099006332","article-title":"Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of \u2018dormancy\u2019, a partial cytostatic effect of the drug, and its implication for treatment regimens","volume":"121","author":"Hoshen","year":"2000","journal-title":"Parasitology"},{"key":"2021081309085885100_dkab181-B19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1073\/pnas.1006113108","article-title":"Intrahost modeling of artemisinin resistance in Plasmodium falciparum","volume":"108","author":"Saralamba","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021081309085885100_dkab181-B20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1475-2875-11-303","article-title":"Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development","volume":"11","author":"Zaloumis","year":"2012","journal-title":"Malar J"},{"key":"2021081309085885100_dkab181-B21","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/jac\/dkw174","article-title":"Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers","volume":"71","author":"McCarthy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021081309085885100_dkab181-B22","doi-asserted-by":"crossref","first-page":"e1002132","DOI":"10.1371\/journal.pbio.1002132","article-title":"Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance","volume":"13","author":"Dogovski","year":"2015","journal-title":"PLoS Biol"},{"key":"2021081309085885100_dkab181-B23","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1073\/pnas.1217452110","article-title":"Altered temporal response of malaria parasites determines differential sensitivity to artemisinin","volume":"110","author":"Klonis","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021081309085885100_dkab181-B24","doi-asserted-by":"crossref","first-page":"11825","DOI":"10.1073\/pnas.172398999","article-title":"Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes","volume":"99","author":"Udomsangpetch","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021081309085885100_dkab181-B25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.pt.2019.05.002","article-title":"Ozonide antimalarial activity in the context of artemisinin-resistant malaria","volume":"35","author":"Giannangelo","year":"2019","journal-title":"Trends Parasitol"},{"key":"2021081309085885100_dkab181-B26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/expr.1993.1010","article-title":"Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria","volume":"76","author":"Terkuile","year":"1993","journal-title":"Exp Parasitol"},{"key":"2021081309085885100_dkab181-B27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"2021081309085885100_dkab181-B28","author":"Lixoft","year":"2019"},{"key":"2021081309085885100_dkab181-B29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","article-title":"Handling data below the limit of quantification in mixed effect models","volume":"11","author":"Bergstrand","year":"2009","journal-title":"AAPS J"},{"key":"2021081309085885100_dkab181-B30","year":"2020"},{"key":"2021081309085885100_dkab181-B31","year":"2020"},{"key":"2021081309085885100_dkab181-B32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021081309085885100_dkab181-B33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12916-017-0940-3","article-title":"A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria","volume":"15","author":"Macintyre","year":"2017","journal-title":"BMC Med"},{"key":"2021081309085885100_dkab181-B34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","article-title":"African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker","volume":"18","author":"Leroy","year":"2019","journal-title":"Malar J"},{"key":"2021081309085885100_dkab181-B35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10852-007-9075-4","article-title":"An age-structured mathematical model for the within host dynamics of malaria and the immune system","volume":"7","author":"Tumwiine","year":"2008","journal-title":"J Math Model Algor"},{"key":"2021081309085885100_dkab181-B36","doi-asserted-by":"crossref","first-page":"e49058","DOI":"10.7554\/eLife.49058","article-title":"Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection","volume":"8","author":"Cao","year":"2019","journal-title":"Elife"},{"key":"2021081309085885100_dkab181-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2004.10.014","article-title":"Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo","volume":"106","author":"Jonker","year":"2005","journal-title":"Pharmacol Ther"},{"key":"2021081309085885100_dkab181-B38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12936-017-1999-1","article-title":"Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model","volume":"16","author":"Wockner","year":"2017","journal-title":"Malar J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2325\/39711719\/dkab181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/9\/2325\/39711719\/dkab181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T05:15:01Z","timestamp":1628831701000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/9\/2325\/6310348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,28]]},"published-print":{"date-parts":[[2021,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab181","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.02.366112","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,28]]}}}